KPV Mechanism of Action
Part of the full KPV guide - a melanocortin-derived c-terminal tripeptide reference compound, identity-verified with a COA on every vial.
In brief
KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone, corresponding to residues 11-13 (Lys-Pro-Val) of the full alpha-MSH molecule. What makes this fragment notable in cell-based research is that its reported anti-inflammatory signaling appears to operate in a largely receptor-independent manner, distinct from the melanocortin-receptor agonism that drives pigmentation in the parent hormone. In cultured intestinal epithelial lines (Caco2-BBE, HT29-Cl.19A) and immune cells, in-vitro studies describe a two-stage mechanism: first, cellular entry through a proton-coupled di/tripeptide transporter, and second, intracellular interference with cytokine-driven transcriptional cascades. The sections below decompose these stages, separating the transporter-uptake step from the downstream signaling effects on NF-kB and MAP kinase pathways, and clarify how this receptor-independent route is positioned relative to classical MC1R signaling in the published cell models.
The detail
A closer look
01
PepT1-mediated cellular entry
A defining feature of KPV in cell-based work is its route of entry. Rather than relying on a surface receptor, in-vitro studies (Dalmasso et al., Gastroenterology 2008) report that the tripeptide is taken up through PepT1 (SLC15A1), the proton-coupled oligopeptide transporter. PepT1 normally moves di- and tripeptides across the apical membrane of intestinal epithelium using an inward proton gradient as the driving force. A relevant detail in the published models is that PepT1 expression is induced in inflamed epithelium, which means the transporter that admits KPV is upregulated precisely in the cellular conditions the studies examine. This transporter-first logic distinguishes KPV from receptor-agonist peptides: the molecule must be internalized to act, framing it as a substrate of a nutrient-peptide transport system rather than a ligand docking at an extracellular binding site.
02
Intracellular NF-kB and MAP kinase attenuation
Once intracellular, the published in-vitro work describes KPV acting on inflammatory signal transduction. At nanomolar concentrations, the tripeptide is reported to attenuate cytokine-stimulated NF-kB and MAP kinase activation in intestinal epithelial and immune cell lines (Dalmasso et al., Gastroenterology 2008). NF-kB is a transcription factor that, when activated by cytokine stimulation, drives expression of pro-inflammatory mediators; MAP kinase cascades feed parallel stress- and inflammation-linked transcriptional programs. By lowering activation of both nodes, KPV is described as reducing transcription of downstream pro-inflammatory products at the cellular level. Importantly, the data characterize this as a receptor-independent action occurring after internalization, which is mechanistically separable from the surface-receptor pharmacology of the full hormone. These remain observations from cultured-cell and preclinical signaling assays.
03
Receptor-independence versus MC1R
The full alpha-MSH hormone signals through melanocortin receptors, with MC1R engagement classically tied to pigmentation. KPV, as the bare C-terminal fragment, is characterized differently. Cell and animal model data (Kannengiesser et al., Inflammatory Bowel Diseases 2008) indicate the tripeptide's anti-inflammatory action is at least partially independent of MC1R signaling, and the mechanism summary notes it does not drive pigmentation as full alpha-MSH does. The mechanistic picture from the cited sources therefore separates two things: the pigment-linked, receptor-mediated arm of the parent hormone, and an MC1R-partially-independent, transporter-then-intracellular-signaling arm attributed to KPV. The literature also references direct antimicrobial and membrane-interaction effects of the alpha-MSH C-terminus, suggesting the fragment can engage targets beyond canonical receptor binding. All of this is framed strictly within in-vitro and preclinical signaling characterization.
The fine print: products are sold for laboratory research use only and are not for human or animal consumption. Bodily introduction into humans or animals is strictly prohibited by law. KPV is not a drug and is not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA.